Karl J Madaras-Kelly1, Muriel Burk2,3, Christina Caplinger4, Jefferson G Bohan4, Melinda M Neuhauser3, Matthew Bidwell Goetz5, Rongping Zhang2, Francesca E Cunningham2,3. 1. Pharmacy Service, Veterans Affairs Medical Center and Department of Pharmacy Practice, College of Pharmacy, Idaho State University, Meridian, Idaho. 2. Center for Medication Safety, Hines VA, Hines, Illinois. 3. VA Pharmacy Benefits Management Services, Hines VA, Hines, Illinois. 4. Pharmacy Service, Veterans Affairs Medical Center, Boise, Idaho. 5. Infectious Diseases Section, VA Greater Los Angeles Health Care System and David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California.
Abstract
OBJECTIVE: Practice guidelines recommend the shortest duration of antimicrobial therapy appropriate to treat uncomplicated pneumonia be prescribed to reduce the emergence of resistant pathogens. A national evaluation was conducted to assess the duration of therapy for pneumonia. DESIGN: Retrospective medication utilization evaluation. SETTING: Thirty Veterans Affairs medical centers. PATIENTS: Inpatients discharged with a diagnosis of pneumonia. MEASUREMENTS: A manual review of electronic medical records of inpatients discharged with uncomplicated community-acquired pneumonia (CAP) or healthcare-associated pneumonia (HCAP) was conducted. Appropriate CAP therapy duration was defined as at least 5 days, and up to 3 additional days beginning the first day the patient achieved clinical stability criteria; the appropriate HCAP therapy duration was defined as 8 days. The duration of antimicrobial therapy for intravenous (IV) and oral (PO) inpatient administration, PO therapy dispensed upon discharge, Clostridium difficile infection (CDI), hospital readmission, and death rates were measured. RESULTS: Of 3881 pneumonia admissions, 1739 met inclusion criteria (CAP [n = 1195]; HCAP [n = 544]). Overall, 13.9% of patients (CAP [6.9%], HCAP [29.0%]) received therapy duration consistent with guideline recommendations. The median (interquartile range) days of therapy were 4 days (3-6 days), 1 day (0-3 days), and 6 days (4-8 days) for inpatient IV, inpatient PO, and outpatient PO antimicrobials, respectively. CDI was rare but more common in patients who received therapy duration consistent with guidelines. Therapy duration was not associated with the readmission or mortality rate. CONCLUSIONS: Antimicrobials were commonly prescribed for a longer duration than guidelines recommend. The majority of excessive therapy was completed upon discharge, identifying the need for strategies to curtail unnecessary use postdischarge. Journal of Hospital Medicine 2015;11:832-839.
OBJECTIVE: Practice guidelines recommend the shortest duration of antimicrobial therapy appropriate to treat uncomplicated pneumonia be prescribed to reduce the emergence of resistant pathogens. A national evaluation was conducted to assess the duration of therapy for pneumonia. DESIGN: Retrospective medication utilization evaluation. SETTING: Thirty Veterans Affairs medical centers. PATIENTS: Inpatients discharged with a diagnosis of pneumonia. MEASUREMENTS: A manual review of electronic medical records of inpatients discharged with uncomplicated community-acquired pneumonia (CAP) or healthcare-associated pneumonia (HCAP) was conducted. Appropriate CAP therapy duration was defined as at least 5 days, and up to 3 additional days beginning the first day the patient achieved clinical stability criteria; the appropriate HCAP therapy duration was defined as 8 days. The duration of antimicrobial therapy for intravenous (IV) and oral (PO) inpatient administration, PO therapy dispensed upon discharge, Clostridium difficileinfection (CDI), hospital readmission, and death rates were measured. RESULTS: Of 3881 pneumonia admissions, 1739 met inclusion criteria (CAP [n = 1195]; HCAP [n = 544]). Overall, 13.9% of patients (CAP [6.9%], HCAP [29.0%]) received therapy duration consistent with guideline recommendations. The median (interquartile range) days of therapy were 4 days (3-6 days), 1 day (0-3 days), and 6 days (4-8 days) for inpatient IV, inpatient PO, and outpatient PO antimicrobials, respectively. CDI was rare but more common in patients who received therapy duration consistent with guidelines. Therapy duration was not associated with the readmission or mortality rate. CONCLUSIONS: Antimicrobials were commonly prescribed for a longer duration than guidelines recommend. The majority of excessive therapy was completed upon discharge, identifying the need for strategies to curtail unnecessary use postdischarge. Journal of Hospital Medicine 2015;11:832-839.
Authors: Sarah H Yi; Kelly M Hatfield; James Baggs; Lauri A Hicks; Arjun Srinivasan; Sujan Reddy; John A Jernigan Journal: Clin Infect Dis Date: 2018-04-17 Impact factor: 9.079
Authors: Christopher J Graber; Makoto M Jones; Matthew Bidwell Goetz; Karl Madaras-Kelly; Yue Zhang; Jorie M Butler; Charlene Weir; Ann F Chou; Sarah Y Youn; Matthew H Samore; Peter A Glassman Journal: Clin Infect Dis Date: 2020-08-22 Impact factor: 9.079
Authors: Barbara E Jones; Candace Haroldsen; Karl Madaras-Kelly; Matthew B Goetz; Jian Ying; Brian Sauer; Makoto M Jones; Molly Leecaster; Tom Greene; Scott K Fridkin; Melinda M Neuhauser; Matthew H Samore Journal: Med Care Date: 2018-07 Impact factor: 2.983
Authors: Caroline C Jozefczyk; W Justin Moore; Paul R Yarnold; Nathaniel J Rhodes; Karolina Harkabuz; Robert Maxwell; Sarah H Sutton; Christina Silkaitis; Chao Qi; Richard G Wunderink; Teresa R Zembower Journal: Antimicrob Agents Chemother Date: 2021-06-17 Impact factor: 5.191
Authors: Valerie M Vaughn; Tejal Gandhi; Anna Conlon; Vineet Chopra; Anurag N Malani; Scott A Flanders Journal: Clin Infect Dis Date: 2019-09-27 Impact factor: 9.079
Authors: Valerie M Vaughn; Tejal N Gandhi; Vineet Chopra; Lindsay A Petty; Daniel L Giesler; Anurag N Malani; Steven J Bernstein; Lama M Hsaiky; Jason M Pogue; Lisa Dumkow; David Ratz; Elizabeth S McLaughlin; Scott A Flanders Journal: Clin Infect Dis Date: 2021-12-06 Impact factor: 9.079
Authors: Shelley S Magill; Erin O'Leary; Susan M Ray; Marion A Kainer; Christopher Evans; Wendy M Bamberg; Helen Johnston; Sarah J Janelle; Tolulope Oyewumi; Ruth Lynfield; Jean Rainbow; Linn Warnke; Joelle Nadle; Deborah L Thompson; Shamima Sharmin; Rebecca Pierce; Alexia Y Zhang; Valerie Ocampo; Meghan Maloney; Samantha Greissman; Lucy E Wilson; Ghinwa Dumyati; Jonathan R Edwards; Nora Chea; Melinda M Neuhauser Journal: JAMA Netw Open Date: 2021-03-01
Authors: Robin M E Janssen; Anke J M Oerlemans; Johannes G Van Der Hoeven; Jaap Ten Oever; Jeroen A Schouten; Marlies E J L Hulscher Journal: J Antimicrob Chemother Date: 2022-07-28 Impact factor: 5.758